Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clindamycin phosphate

Pharmaceutical Development and Technology

Volumn 15, Issue 4, 2010, Pages 405-414

  Dobaria, Nitin ^a   Mashru, Rajashree ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

bioadhesion; bioadhesive vaginal film; Clindamycin phosphate; desirability function; factorial design

Indexed keywords

ADHESIVE AGENT; CLINDAMYCIN PHOSPHATE; HYDROXYPROPYLCELLULOSE; PLASTICIZER; XANTHAN; ANTIINFECTIVE AGENT; BACTERIAL POLYSACCHARIDE; CELLULOSE; CLINDAMYCIN; DELAYED RELEASE FORMULATION; EXCIPIENT;

ARTICLE; BIOFILM; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FACTORIAL DESIGN; HUMAN; HUMAN CELL; IN VITRO STUDY; MOISTURE; PRIORITY JOURNAL; TENSILE STRENGTH; VAGINA MUCOSA; VAGINAL FILM; VAGINITIS; ADHESION; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; HELA CELL LINE; INTRAVAGINAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; MUCOSA; PROCEDURES; SHEEP; TIME; TOXICITY; VAGINOSIS, BACTERIAL;

ADHESIVENESS; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-BACTERIAL AGENTS; CELL SURVIVAL; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CLINDAMYCIN; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; FEMALE; HELA CELLS; HUMANS; MUCOUS MEMBRANE; POLYSACCHARIDES, BACTERIAL; SHEEP; TENSILE STRENGTH; TIME FACTORS; VAGINOSIS, BACTERIAL;

EID: 77953984131     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903262058     Document Type: Article

References (41)

1. Eschenbach DA. History and review of bacterial vaginosis. Am J Obstet Gynecol 1993;169:441-445.
2. Priestly CJF, Kinghorn GR. Bacterial vaginosis. Br J Clin Pract 1996;50:331-334.
3. Mead PB. Epidemiology of bacterial vaginosis. Am J Obstet Gynecol 1993;169:446-449.
4. Schmid G, Markowitz L, Joesoef R, Koumans E. Bacterial vaginosis and HIV infection. Sex Transm Infect 2000;76:3-4.
5. Peipert J, Montagno A, Cooper A, Sung C. Bacterial vaginosis as a risk factor for upper genital tract. Am J Obstet Gynecol 1997;177:1184-1187.
6. Larsson P, Platz-Christensen J, Thejls H, Forsum U, Pahlson C. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: A double blind, randomized study. Am J Obstet Gynecol 1992;166:100-103.
7. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Yang LP. Bacterial vaginosis and disturbances of vaginal flora: Association with increased acquisition of HIV. AIDS 1998;12:1699-1706.
8. Royce RA, Thorp J, Granados JL, Savitz DA. Bacterial vaginosis associated with HIV infection in pregnant women from North Carolina. J Acquir Immun Defic Syndr Hum Retrovirol 1999;20:382-386.
9. Hillier SL. Treatment of bacterial vaginosis. Female Patient 1995;5:6-16.
10. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: Review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999;28:S57-65.
11. Saracoglu F, Gol K, Sahin I, Turkkani B, Atalay C, Oztopcu C. Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole. Int J Gynecol Obstet 1998;62:59-61.
12. Borin MT, Powley GW, Tackwell KR, Batts DH. Absorption of clindamycin after intravaginal application of clindamycin phosphate 2% cream. J Antimicrob Chemother 1995;35:833-841.
13. Livengood CH, Thomason JL, Hill GB. Bacterial vaginosis: Treatment with topical intravaginal clindamycin phosphate. Obstet Gynecol 1990;76:118-123.
14. Eschenbach DA, Critchlow CW, Watkins H, Smith K, Spiegel CA, Chen KCS, Holmes KK. A dose-duration study of metronidazole for the treatment of nonspecific vaginosis. Scand J Infect Dis (Suppl,) 1983;40:73-80.
15. Greaves WL, Chungagung J, Morris B, Haile A, Townsend JL. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988;72:799-802.
16. Ahmed-Jusuf IH, Shahmanesh M, Arya OP. The treatment of bacterial vaginosis with a three day course of 2% clindamycin cream: Results of a multicentre, double blind, placebo controlled trial. Genitourin Med 1995;71:254-256.
17. Rosenstein IJ, Morgan DJ, Lamont RF. Effect of vaginally applied clindamycin on vaginal microbial flora and outcome of pregnancy in women with bacterial vaginosis. Infect Dis Obstet Gynecol 2000;8:158-165.
18. Ronald F, Lamont L, Brian MJ, Mandalay D, Philip EH, Marie S. The efficacy of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy. Infect Dis Obstet Gynecol 2003;11:181-189.
19. Paavonen J, Mangioni C, Martin MA, Wajszczuk CP,Vaginal clindamycin and oral metronidazole for bacterial vaginosis: A randomized trial. Obstet Gynecol 2000;96:256-260.
20. Andres FJ, Parker R, Hosein I, Benrubi GI. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: A prospective double-blind clinical trial. South Med J 1992;85:1077-1080.
21. Fischbach F, Petersen EE, Weissenbacher ER, Martius J, Hosmann J, Mayer H. Efficacy of clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1993;82:405-410.
22. Vermani K, Garg S, Zaneveld LJD, Tambwekar KR. Survey of vaginal formulations available in Indian market; physicochemical characterization of selected products. Int J Pharm Med 2002;16:141-152.
23. Henderson MH, Couchman GM, Walmer DK, Peters JJ, Owen DH, Brown MA, Lavine ML, Katzab DF. Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception 2007;75:142-151.
24. Ceschel GC, Maffei P, Barcia SL, Ronchi C, Rossi S. Development of a mucoadhesive dosage form for vaginal administration. Drug Dev Ind Pharm 2001;27:541-547.
25. Kast CE, Valenta C, Leopold M, Bernkop-Schnürch A. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for CLT. J Cont Rel 2002;81:347-354.
26. Garg S, Kandarapu R, Vermani K, Tambwekar KR. Development pharmaceutics of microbicide formulations part I: Preformulation considerations and challenges. AIDS Patient Care STDS 2003;17:17-32. (Pubitemid 36083819)
27. Coggins C, Elias CJ, Atisook R, Bassett MT, Ghys PD, Jenkins- Woelk L, Thongkrajai E, Van Devanter NL. Women's preferences regarding the formulation of over the counter vaginal spermicides. AIDS 1998;12:1389-1391.
28. Owen DH, Katz DF. A vaginal fluid stimulant. Contraception 1999;59:91-95.
29. Garg S, Vermani K, Garg A, Anderson RA, Rencher BW, Zaneveld LJD. Development and characterization of bioadheive vaginal films of sodium polystyrene sufonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res 2005;22:584-595.
30. Mashru RC, Sutariya VB, Sankalia MG, Parikh PP. Development and evaluation of fast-dissolving film of salbutamol sulphate. Drug Dev Ind Pharm 2005;1:25-34.
31. Derringer G, Suich R. Simultaneous optimization of several responses variables. J Quality Technol 1980;12:214-219.
32. Repka AM, McGinity JW. Physical-mechanical, moisture absorption and bioadhesive properties of hydroxypropylcellulose hotmelt extruded films. Biomaterials 2000;21:509-1517.
33. Peh KK, Wong CF. Polymeric films as vehicle for buccal delivery: Swelling, mechanical, and bioadhesive properties. J Pharmacy Pharm Sci 1999;2:53-61.
34. Gatti G, Malena M, Casazza R, Borin M, Bassetti M, Cruciani M. Penetration of clindamycin and its metabolite n-demethylclindamycin into cerebrospinal fluid following intravenous infusion of Clindamycin phosphate in patients with AIDS. J Antimicrob Chemother 1998;42:3014-3017.
35. Jin-Wook Y, Dharmala K, Lee CH. The physicodynamic properties of bioadhesive polymeric films developed as female controlled drug delivery system. Int J Pharm 2006;309:139-141.
36. Gannu R, Vishnu YV, Kishan V, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Curr Drug Deliv 2007;4:69-76.
37. Dobaria N, Mashru R, Vadia NH. Vaginal drug delivery systems: A review of current Status. East Cent Afr J Pharm Sci 2007;10:3-13.
38. Alam MA, Ahmad FJ, Khan ZI, Khar RK, Ali M. Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPS PharmSciTech. 2007;8: Article 109.
39. Lei W, Xing T. A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: Design, in vitro and 'in vivo' evaluation. Inter J Pharm 2008;350:181-187.
40. Reddy KVR, Aranha C, Gupta SM, Yedery RD. Evaluation of antimicrobial peptide Nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo studies. Reproduction 2004;128:117-126.
41. Korting HC, Schindler S, Hartinger A, Kerscher M, Maibatch HI. MTT assay and neutral red release (NRR) assay: Relative role in the prediction of the irritancy potential of surfactants. Life Sci 1994;55:533-540.